Citius Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Clear Secure Inc trades at $54.17 (market cap $5.39B). The key difference: Clear Secure Inc is far larger — about 368.2× Citius Pharmaceuticals Inc's market cap, and Clear Secure Inc pays a 1.12% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | YOU | |
|---|---|---|
Market Cap | $14.64M | $5.39B |
Sector | Health | Technology |
52-Week High | $1.82 | $62.36 |
52-Week Low | $0.53 | $28.84 |
Enterprise Value | $10.86M | $4.71B |
Dividend Yield | — | 1.12% |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Clear Secure (YOU) trades at $53.08, down 3.88% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 65.48% gross margins and impressive 81.15% ROE. Recent Q1 2026 earnings beat expectations at $0.38 EPS versus $0.35 expected, while analysts maintain a mixed consensus with 44% buy ratings and a $56.67 price target. The company continues expanding its airport security services with recent launches in Indianapolis and Miami.
YOU presents a compelling growth story with expanding revenue and profitability, though elevated valuation multiples (P/E 42.83) warrant caution. Near-term catalysts include Q2 earnings and continued airport expansion, while risks involve execution challenges and market volatility. The stock offers potential upside to analyst targets but requires monitoring of earnings consistency.
Trailing returns across standard periods
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →